Events
Save the Date: An Exclusive Xturnpoint Event
Wednesday, July 16 2025
The XTMAB16 Study is currently researching pulmonary sarcoidosis. Learn about a study medication that may help treat this rare disease.
We are a biotech company building authentic life-sciences partnerships to guide innovative drug and intellectual property development from early concepts through clinical development and towards commercial launch.
Who We AreWhat We Do
We reinvent how life-sciences partnerships can deliver adaptive approaches to ambitious drug innovation for improved patient outcomes.
Guiding Your ConceptOur Portfolio
Our current pipeline represents how our partnerships guide ambitious developers through challenging drug projects.
View PipelineXTMAB-16
Discover how tenacity, expertise, and partnerships built on trust drove Xentria’s development of an Investigational New Drug (IND) candidate aimed to suppress the physiologic response tumor necrosis factor (TNF).
View the JourneyLife at Xentria
We are a growing team of resourceful innovators who embrace those with the desire to engage, adapt, serve and solve. Find out how you can apply your talents to advance the development of needed drugs with challenging profiles. The results of your work are noticed, and you can see the difference they make.
Be Part of Our TeamNews & Events
.jpg)
Pipeline
Xentria Advances XTMAB16 Study in Pulmonary Sarcoidosis with Completed Enrollment and Key Conference Selections
March 18, 2025
Pipeline
Expanding Horizons: Xentria Achieves Milestone Success with Biosimilar Development
January 8, 2025
Pipeline
Xentria Announces Exclusive Licensing Agreement with New York University to Advance a Disease-Modifying Cardiovascular Therapy Globally
December 19, 2024